Wyeth will transfer Relistor back to Progenics along with $10M within a year and Progenics immediately take over development of an oral formulation. <a href="http://www.reuters.com/article/americasRegulatoryNews/idUSN1320573420091014" rel="nofollow" target="_blank">http://www.reuters.com/article/americasRegulatoryNews/idUSN1320573420091014</a>